Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI110 Plus Sintilimab and Chemotherapy in Untreated ES-SCLC
NCT05026593Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Sep 2021
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ibi110 in small cell lung cancer (SCLC) (2 arms), sponsored by Innovent Biologics. Primary endpoints: Progression-Free Survival up to 5 years and Incidence of Treatment-related Adverse Events, Serious Adverse Events and Immune-related adverse events up to 5 years. Started Sep 2021; status: completed.
02
Drugs
ibi110
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05026593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05026593.